PIII
A rare “we’re actually improving” quarter
P3 Health Partners kicked off 2026 by saying Q1 was a meaningful turning point. The headline number: $26 million in adjusted EBITDA, which is the kind of metric management loves because it says the business is squeezing more profit out of the same machine.
Why that matters
For a company like P3, investors aren’t just watching revenue; they’re watching whether the whole population-health engine can get lean enough to throw off real earnings power. Management pointed to two years of work behind the scenes — things like contract restructuring and tighter network concentration — finally showing up in the numbers.
The investor takeaway
That’s the sort of update that can help a beaten-up story stock get a little credit back from the market. But the real question is whether this was a one-quarter flex or the beginning of a trend. If P3 can keep the improvement going, the market may start treating it less like a fix-it project and more like a business with actual operating leverage.
Big picture: P3 is trying to turn “promising turnaround” into “show me the margin.” And for investors, that’s where the story gets interesting.